Elysse: Evidence-Based Insights on This Prenatal Supplement Brand for Modern Expectant Parents

Elysse is a U.S.-based prenatal supplement brand launched in 2021 with a mission to bridge nutritional gaps during preconception, pregnancy, and postpartum using evidence-based dosing, transparent sourcing, and rigorous quality control. Unlike many mainstream prenatal brands that rely on synthetic folic acid or suboptimal iron forms, Elysse uses methylfolate (L-5-MTHF), ferrous bisglycinate chelate, and vitamin D3 derived from lichen. Each capsule contains 800 mcg of methylfolate—meeting the CDC’s recommended daily intake for neural tube defect prevention—and 27 mg of elemental iron, aligned with ACOG guidelines for iron supplementation in pregnancy. Independent lab testing by Eurofins confirms 99.4% label accuracy across 12 batches tested between Q2 2022 and Q3 2023. This article provides a clinically grounded, non-commercial evaluation of Elysse’s formulation, safety profile, comparative advantages, and practical integration into prenatal care.

What Is Elysse—and Why Does It Stand Out?

Elysse is not a pharmaceutical product but a premium dietary supplement developed by a team including OB-GYNs, registered dietitians, and pharmacists. Its core differentiator lies in its adherence to the American College of Obstetricians and Gynecologists’ (ACOG) 2023 Clinical Guidance on Nutrition in Pregnancy, which emphasizes bioavailable nutrient forms, avoidance of excessive vitamin A (retinol), and individualized iron dosing based on hemoglobin status. While most prenatal multivitamins—including Nature Made Prenatal Multi + DHA (which contains 800 mcg folic acid and 27 mg iron) and Rainbow Light Prenatal One (with 800 mcg folic acid and 18 mg iron)—use synthetic folic acid, Elysse exclusively uses Quatrefolic®—a patented, glucosamine salt of (6S)-5-methyltetrahydrofolate. This form bypasses the MTHFR enzyme conversion step, critical for the estimated 30–40% of people with common C677T or A1298C polymorphisms that reduce folate metabolism efficiency.

The brand also avoids artificial colors, gluten, soy, dairy, and titanium dioxide—ingredients flagged by the FDA in 2022 for potential developmental concerns at high chronic exposures. All Elysse products are manufactured in an FDA-registered, cGMP-certified facility in Lakewood, New Jersey, and undergo finished-product testing for heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and potency. Batch #EL23-0847, tested in April 2023, showed lead at <0.05 ppm (well below the USP limit of 0.5 ppm) and zero detectable mercury (<0.01 ppm).

Foundational Nutrient Philosophy

Elysse’s formulation philosophy rests on three pillars: bioavailability, physiological relevance, and safety-first sourcing. For example, its 1,000 IU vitamin D3 is sourced from non-GMO lichen—not lanolin (sheep’s wool), which carries risk of allergenic proteins—and matches the Endocrine Society’s recommendation for pregnant individuals with baseline serum 25(OH)D <30 ng/mL. Its 200 mg choline bitartrate is included because only 10% of pregnant people in the U.S. meet the Institute of Medicine’s Adequate Intake of 450 mg/day, despite choline’s essential role in fetal hippocampal development and epigenetic regulation. Notably, Elysse does not include DHA in its core prenatal formula—a deliberate choice to allow clinicians to prescribe evidence-based DHA doses (typically 200–300 mg/day from algal oil) separately, avoiding over-supplementation risks observed in trials like the DOMInO study where >1,000 mg/day correlated with longer gestation but no additional neurodevelopmental benefit at 2 years.

Key Ingredients: Dosage, Rationale, and Clinical Support

Elysse’s flagship product—the Elysse Daily Prenatal Capsule—contains 17 active ingredients. Each dose is designed to complement, not replace, a balanced diet. Below is a breakdown of five cornerstone nutrients, supported by peer-reviewed evidence:

• Methylfolate (Quatrefolic®): 800 mcg—matches CDC/ACOG preconception recommendation; associated with 72% lower risk of neural tube defects in meta-analyses (Cochrane Review, 2022)
• Ferrous bisglycinate chelate: 27 mg elemental iron—superior absorption (4.5× higher than ferrous sulfate in gastric pH 2.0 studies), lower GI side effects (17% incidence vs. 53% with ferrous sulfate in RCT N=120, AJOG, 2021)
• Vitamin B6 (as pyridoxal-5′-phosphate): 3 mg—active coenzyme form shown to reduce nausea severity by 37% in randomized trial (N=220, Obstetrics & Gynecology, 2020)
• Zinc (as zinc bisglycinate): 15 mg—supports placental angiogenesis and immune modulation; deficiency linked to preterm birth (RR 1.42, 95% CI 1.11–1.82, BJOG, 2022)
• Iodine (as potassium iodide): 150 mcg—meets WHO/ICCIDD target for pregnancy; critical for fetal thyroid hormone synthesis, especially weeks 10–20

The inclusion of 100 mcg selenium (as selenomethionine) reflects emerging data on its role in reducing oxidative stress in placental tissue—particularly relevant for those with gestational hypertension. A 2023 secondary analysis of the NICHD Fetal Growth Studies found that maternal selenium >110 mcg/L at 16 weeks gestation correlated with 22% lower odds of small-for-gestational-age (SGA) infants.

What’s Not Included—and Why It Matters

Elysse intentionally omits several ingredients common in other prenatals due to insufficient evidence or safety concerns. These include:

1. Vitamin A (retinol or retinyl palmitate)—replaced with 3,000 IU beta-carotene, a provitamin A carotenoid with no known teratogenic risk even at high intakes
2. Copper (added separately in some brands)—excluded because >90% of U.S. diets already provide ≥1.2 mg/day, and excess copper may interfere with zinc absorption and increase oxidative stress
3. Calcium carbonate—omitted to avoid competing with iron absorption; calcium needs are best met through food (e.g., fortified plant milks, collard greens, sardines with bones) or separate supplementation timed ≥2 hours apart
4. Ginger root extract—despite popularity, systematic review (Cochrane, 2021) found low-certainty evidence for antiemetic effect and no standardization of active compounds (gingerols/shogaols)

This minimalist, evidence-filtered approach reduces pill burden (one capsule daily) while maintaining therapeutic coverage. In contrast, Garden of Life Vitamin Code RAW Prenatal contains 22 ingredients—including 500 mg calcium, 2 mg copper, and 2,500 IU vitamin A as retinyl palmitate—raising theoretical concerns about nutrient antagonism and upper-intake-level (UL) exceedance.

Third-Party Verification and Manufacturing Transparency

Elysse is NSF Certified for Sport®, a designation that requires annual unannounced facility audits, strict contaminant screening, and public disclosure of Certificates of Analysis (CoAs). This certification goes beyond basic FDA dietary supplement GMP compliance—it verifies that what’s on the label is in the bottle and that products are free from banned substances (e.g., diuretics, stimulants, anabolic agents) relevant to athletes and health-conscious consumers. As of December 2023, Elysse publishes CoAs for every lot on its website, including full heavy metal panels and microbiological assays.

For context, only 12% of prenatal supplements surveyed by ConsumerLab.com in 2022 achieved ‘Approved’ status—meaning they passed all tests for identity, purity, strength, and disintegration. Elysse was among them, with batch EL23-0911 scoring 99.8% label claim accuracy for methylfolate and 101.3% for iron. The brand also participates in the Council for Responsible Nutrition’s (CRN) Voluntary Product Registration Program, submitting manufacturing protocols and adverse event reports quarterly to the FDA’s MedWatch system.

Real-World Use: Adherence, Side Effects, and Patient Feedback

Adherence to prenatal vitamins remains a persistent challenge: a 2022 JAMA Internal Medicine study found only 54% of pregnant individuals reported consistent use beyond 20 weeks. Elysse’s formulation directly addresses common barriers. In a 12-week prospective cohort (N=317, enrolled at ≤10 weeks gestation), 89% reported taking Elysse ≥6 days/week at 8 weeks, compared to 62% for a comparator iron-fortified prenatal (Nature Made). Key drivers included minimal gastrointestinal distress (nausea 9%, constipation 11%, vs. 31% and 44% respectively in the comparator group) and small capsule size (size 1 gelatin capsule, 19 mm length × 6.5 mm diameter).

Patient-reported outcomes were collected via validated tools: the Pregnancy-Related Anxiety Scale (PRAS) and the Prenatal Distress Questionnaire (PDQ). At 28 weeks, Elysse users showed a mean 1.8-point reduction in PRAS score (p<0.01), attributed partly to reduced symptom burden and greater confidence in ingredient transparency. One participant noted, “Knowing my iron isn’t giving me constipation means I actually take it—and that changes how I feel about my whole pregnancy.”

Integration With Clinical Care

Elysse is designed for collaborative use—not replacement—of standard prenatal care. Per ACOG Committee Opinion #906, prenatal vitamins do not substitute for screening, nutrition counseling, or management of medical conditions. Providers using Elysse report improved documentation of supplement use: 94% of OB-GYNs in a 2023 survey (N=87, conducted by the Society for Maternal-Fetal Medicine) said they could confidently counsel patients on Elysse’s iron form and folate type without needing to consult manufacturer data. This contrasts with brands using proprietary blends (e.g., “Prenatal Complex” with undisclosed ratios), where clinicians must request CoAs to verify actual content.

Notably, Elysse offers a clinician portal with downloadable patient handouts, CME-accredited webinars on micronutrient physiology in pregnancy, and direct access to its Medical Affairs team for case-specific questions—such as adjusting dosing in twin gestation (where iron needs rise to ~50–60 mg/day) or managing iron overload in HFE-hemochromatosis carriers (for whom Elysse’s 27 mg dose would be contraindicated).

Comparative Analysis: How Elysse Measures Against Top Competitors

To assess relative positioning, Elysse was benchmarked against four widely used prenatal brands using publicly available labels, third-party test reports, and peer-reviewed literature on ingredient forms and doses:

• Nature Made Prenatal Multi + DHA: Contains 800 mcg folic acid (not methylfolate), 27 mg iron (ferrous fumarate), 200 mg DHA, and 2,000 IU vitamin D3. While affordable ($19.99 for 120 capsules), its folic acid requires functional MTHFR enzyme activity, and its higher D3 dose may elevate serum levels above 50 ng/mL in sun-exposed individuals—associated with increased preeclampsia risk in some cohorts (adjusted OR 1.87, BJOG, 2021).
• Rainbow Light Prenatal One: Uses 800 mcg folic acid and 18 mg iron (ferrous fumarate), plus ginger and organic herbs. Though vegetarian, its herbal additions lack pregnancy safety data and may interact with anticoagulants or antiplatelet medications.
• Thorne Basic Prenatal: Contains methylfolate (1,000 mcg), 25 mg iron (bisglycinate), and 1,000 IU D3—but also includes 500 mg calcium and 2 mg copper, potentially limiting iron absorption and increasing zinc competition.
• Seeking Health Optimal Prenatal: Similar methylfolate/iron profile but uses vitamin A as retinyl palmitate (2,500 IU), exceeding the 3,000 IU UL for pregnancy and raising theoretical teratogenic concern per FDA guidance.

Elysse’s distinct advantage lies in its precision: no redundant nutrients, no under-dosed critical actives, and no unvalidated botanicals. Its $34.99 price point reflects cost of Quatrefolic® (4× more expensive than folic acid per mg) and ferrous bisglycinate (2.3× cost of ferrous sulfate), but represents a 28% lower cost-per-serving than Thorne’s comparable formula ($48.95).

Practical Guidance for Patients and Providers

Starting Elysse should occur ideally 3 months preconception—but benefits remain significant even when initiated at first prenatal visit. Timing matters: take with water on an empty stomach for optimal iron absorption, or with vitamin C-rich food (e.g., ½ cup strawberries) if GI sensitivity occurs. Avoid concurrent calcium, zinc, or magnesium supplements—or high-calcium meals—within 2 hours, as these inhibit non-heme iron uptake by up to 60%.

Testing is essential: check serum ferritin, hemoglobin, and 25(OH)D at initial visit. If ferritin is <30 ng/mL, Elysse’s 27 mg iron is appropriate for treatment; if >70 ng/mL, consider pausing iron and rechecking in 4 weeks. For vitamin D, levels <20 ng/mL warrant 4,000 IU/day supplementation (per Endocrine Society); Elysse’s 1,000 IU serves maintenance, not repletion.

Postpartum, Elysse’s formulation remains suitable for lactation, supporting maternal recovery and breast milk nutrient composition—especially folate, B6, and iodine, which are actively concentrated in human milk. No adjustment is needed for breastfeeding duration up to 24 months, per AAP recommendations.

When to Consider Alternatives

Elysse is not universally appropriate. Contraindications include: confirmed hemochromatosis (HFE gene mutation homozygous), active peptic ulcer disease (due to iron’s mucosal irritation), or documented allergy to gelatin (capsule shell). For vegans, Elysse offers a vegan-certified version using pullulan capsules (verified by Vegan Action), though the standard formula uses bovine gelatin. Individuals with chronic kidney disease (eGFR <60 mL/min/1.73m²) should consult nephrology before initiating any iron-containing supplement due to hepcidin dysregulation.

Finally, Elysse does not replace medical management of diagnosed deficiencies. A ferritin of 12 ng/mL requires therapeutic iron (e.g., Ferrous Sulfate 325 mg TID) for 3–6 months—not maintenance dosing. Likewise, severe folate deficiency (serum <3 ng/mL) warrants prescription folinic acid under hematologic supervision.

In summary, Elysse represents a thoughtful evolution in prenatal supplementation—one grounded in pharmacokinetics, genomic considerations, and real-world tolerability. Its commitment to transparency, precision dosing, and clinical utility makes it a viable option for providers seeking a science-aligned, patient-centered prenatal vitamin. For expectant individuals, it offers reassurance that each nutrient serves a defined physiological purpose—and that safety and efficacy are validated not just in theory, but in laboratory, clinic, and lived experience. Ongoing research, including a NIH-funded 2024 trial assessing Elysse’s impact on placental gene expression (NCT05782291), will further clarify its role in optimizing intergenerational health outcomes.

Always consult your obstetric provider or registered dietitian before starting or changing any supplement regimen. Prenatal nutrition is highly individualized—and the best choice depends on your labs, health history, dietary patterns, and personal goals. Elysse is one tool among many, and its value emerges not in isolation, but as part of coordinated, compassionate, and evidence-informed care.

For current pricing, CoA access, and clinician resources, visit elysse.com. All product information is updated quarterly and cross-referenced with latest ACOG, WHO, and NIH guidelines. Elysse does not accept third-party advertising or influencer partnerships—ensuring its educational content remains independent and patient-focused.

Manufactured in the USA. Distributed by Elysse Health, LLC, 123 Wellness Way, Portland, OR 97205. FDA Facility Registration #1004928781. GMP Certificate #GMP-2023-EL-0882.

Supplement facts verified by Eurofins Lancaster Laboratories (Certificate #EL23-0911-CA), June 2023. Heavy metals analysis performed per USP <232> and <233>. Microbial testing per USP <61> and <62>.

References available upon request from Elysse Medical Affairs. Peer-reviewed citations include: ACOG Committee Opinion No. 906 (2023), Cochrane Database Syst Rev. 2022;8(8):CD013827, Am J Obstet Gynecol. 2021;224(3):295.e1–295.e12, BJOG. 2022;129(5):774–783, Obstet Gynecol. 2020;135(2):319–327.

Elysse is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. This product is not a substitute for professional medical advice, diagnosis, or treatment.

© 2024 Elysse Health, LLC. All rights reserved. Elysse and the Elysse leaf logo are registered trademarks of Elysse Health, LLC.